Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of prior KYV-101 recipients
2024-511198-31-00Phase 3Authorised
- Sponsor
- Kyverna Therapeutics
- Start
- Mar 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of mivocabtagene autoleucel in myasthenia gravis (MG), rheumatoid arthritis (RA), lupus nephritis (LN) and 2 more, sponsored by Kyverna Therapeutics. Primary endpoints: Incidence of adverse events, Persistence of KYV-101 and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
mivocabtagene autoleucel
03
Conditions
myasthenia gravis (MG)rheumatoid arthritis (RA)lupus nephritis (LN)systemic sclerosis (SSc)stiff person syndrome (SPS)
Beyond the preview
Go deeper on 2024-511198-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511198-31-00.